JP2013539468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539468A5 JP2013539468A5 JP2013526189A JP2013526189A JP2013539468A5 JP 2013539468 A5 JP2013539468 A5 JP 2013539468A5 JP 2013526189 A JP2013526189 A JP 2013526189A JP 2013526189 A JP2013526189 A JP 2013526189A JP 2013539468 A5 JP2013539468 A5 JP 2013539468A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- item
- seq
- notum
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 claims description 82
- 101150025249 Notum gene Proteins 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 210000000130 stem cell Anatomy 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 238000007798 limiting dilution analysis Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000001613 neoplastic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 5
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000013115 immunohistochemical detection Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 3
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 3
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000018732 detection of tumor cell Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 238000011002 quantification Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000014306 paracrine signaling Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37788210P | 2010-08-27 | 2010-08-27 | |
| US61/377,882 | 2010-08-27 | ||
| US38018110P | 2010-09-03 | 2010-09-03 | |
| US61/380,181 | 2010-09-03 | ||
| US38855210P | 2010-09-30 | 2010-09-30 | |
| US61/388,552 | 2010-09-30 | ||
| US201161510413P | 2011-07-21 | 2011-07-21 | |
| US61/510,413 | 2011-07-21 | ||
| PCT/US2011/049458 WO2012027723A1 (en) | 2010-08-27 | 2011-08-26 | Notum protein modulators and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030708A Division JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013539468A JP2013539468A (ja) | 2013-10-24 |
| JP2013539468A5 true JP2013539468A5 (enExample) | 2014-10-09 |
Family
ID=44741704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526189A Ceased JP2013539468A (ja) | 2010-08-27 | 2011-08-26 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
| JP2016030708A Pending JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016030708A Pending JP2016119906A (ja) | 2010-08-27 | 2016-02-22 | Ｎｏｔｕｍタンパク質モジュレーターおよび使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130224191A1 (enExample) |
| EP (1) | EP2608807A1 (enExample) |
| JP (2) | JP2013539468A (enExample) |
| KR (1) | KR20140018837A (enExample) |
| CN (1) | CN103260646B (enExample) |
| AU (2) | AU2011293127B2 (enExample) |
| BR (1) | BR112013004776A2 (enExample) |
| CA (1) | CA2809369A1 (enExample) |
| CO (1) | CO6700829A2 (enExample) |
| MX (1) | MX2013002255A (enExample) |
| PE (1) | PE20140190A1 (enExample) |
| PH (1) | PH12013500379A1 (enExample) |
| RU (1) | RU2013113638A (enExample) |
| SG (2) | SG10201506782XA (enExample) |
| WO (1) | WO2012027723A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120266260A1 (en) * | 2009-05-26 | 2012-10-18 | Hitoshi Suzuki | Diagnosing and treating iga nephropathy |
| SG10201506782XA (en) * | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| CA2809864A1 (en) * | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| MX385858B (es) * | 2010-11-24 | 2025-03-18 | Lexicon Pharmaceuticals Inc | Anticuerpos que se unen a notum pectinacetilesterasa. |
| US8802365B2 (en) * | 2011-03-22 | 2014-08-12 | Whitehead Institute For Biomedical Research | Methods for identifying candidate modulators of NOTUM activity |
| WO2013004841A1 (en) * | 2011-07-06 | 2013-01-10 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
| EP2961853B1 (en) * | 2013-02-28 | 2018-09-19 | The Board of Regents of The University of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
| WO2015054427A1 (en) | 2013-10-10 | 2015-04-16 | Beth Israel Deaconess Medical Center, Inc. | Tm4sf1 binding proteins and methods of using same |
| AU2014346695B2 (en) * | 2013-11-06 | 2020-10-15 | Astute Medical, Inc. | Assays for IGFBP7 having improved performance in biological samples |
| EP3105251A4 (en) * | 2014-02-10 | 2017-11-15 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
| KR20150105505A (ko) * | 2014-03-06 | 2015-09-17 | (주)노바셀테크놀로지 | 신규 대장암의 바이오마커 및 그를 표적으로 하는 항암제 |
| WO2015200522A2 (en) * | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| CA3021047A1 (en) * | 2016-05-09 | 2017-11-16 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof |
| EP3585403A4 (en) * | 2017-02-22 | 2020-12-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHEMERICAL ANTIGENIC RECEPTORS BINDING TO TIM3 |
| MX2019011252A (es) * | 2017-03-23 | 2020-01-23 | Univ Pennsylvania | Anticuerpos anti-c5a y usos de los mismos. |
| US11525004B2 (en) | 2017-07-20 | 2022-12-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant CD123-binding antibodies |
| CA3143995A1 (en) * | 2019-06-21 | 2020-12-24 | Single Cell Technology, Inc. | Anti-tigit antibodies |
| CN110950960B (zh) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 |
| WO2021242757A1 (en) * | 2020-05-26 | 2021-12-02 | The Trustees Of The University Of Pennsylvania | Monocolonal antibodies against pathological tau, and methods using same |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CN117430702B (zh) * | 2022-07-21 | 2024-06-21 | 东莞市朋志生物科技有限公司 | 抗b型尿钠肽抗体或其功能性片段、检测b型尿钠肽的试剂和试剂盒 |
| CN121464157A (zh) * | 2023-02-28 | 2026-02-03 | 梅约医学教育与研究基金会 | 结合至b细胞活化因子受体多肽的分子 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE145428T1 (de) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| CZ25697A3 (en) | 1994-07-29 | 1997-09-17 | Smithkline Beecham Plc | Novel compounds |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1992633A1 (en) | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| ATE428733T1 (de) * | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| BR0210904A (pt) | 2001-05-16 | 2005-08-16 | Yeda Res & Dev | Uso de inibidores de il-18 para o tratamento ou prevenção de sepse |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| GB0201808D0 (en) * | 2002-01-25 | 2002-03-13 | European Molecular Biology Lab Embl | Protein |
| JP2005533001A (ja) | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7371840B2 (en) * | 2003-01-08 | 2008-05-13 | The University Of Southern California | Isolation and characterization of ECA1, a gene overexpressed in endometrioid carcinomas of ovary and endometrium |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| ATE528397T1 (de) * | 2003-08-08 | 2011-10-15 | Perseus Proteomics Inc | Bei krebs überexprimiertes gen |
| US20070037204A1 (en) * | 2003-08-08 | 2007-02-15 | Hiroyuki ABURANTAI | Gene overexpressed in cancer |
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| WO2007145901A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| EP3207941B3 (en) | 2006-09-07 | 2020-08-19 | Scott & White Memorial Hospital | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| SG10201506782XA (en) * | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
| MX385858B (es) * | 2010-11-24 | 2025-03-18 | Lexicon Pharmaceuticals Inc | Anticuerpos que se unen a notum pectinacetilesterasa. |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-08-26 SG SG10201506782XA patent/SG10201506782XA/en unknown
- 2011-08-26 PH PH1/2013/500379A patent/PH12013500379A1/en unknown
- 2011-08-26 CN CN201180052205.9A patent/CN103260646B/zh not_active Expired - Fee Related
- 2011-08-26 US US13/819,208 patent/US20130224191A1/en not_active Abandoned
- 2011-08-26 MX MX2013002255A patent/MX2013002255A/es unknown
- 2011-08-26 RU RU2013113638/10A patent/RU2013113638A/ru not_active Application Discontinuation
- 2011-08-26 PE PE2013000347A patent/PE20140190A1/es not_active Application Discontinuation
- 2011-08-26 SG SG2013014261A patent/SG187965A1/en unknown
- 2011-08-26 WO PCT/US2011/049458 patent/WO2012027723A1/en not_active Ceased
- 2011-08-26 EP EP11752429.8A patent/EP2608807A1/en not_active Withdrawn
- 2011-08-26 AU AU2011293127A patent/AU2011293127B2/en not_active Ceased
- 2011-08-26 BR BR112013004776A patent/BR112013004776A2/pt not_active Application Discontinuation
- 2011-08-26 JP JP2013526189A patent/JP2013539468A/ja not_active Ceased
- 2011-08-26 KR KR1020137007609A patent/KR20140018837A/ko not_active Withdrawn
- 2011-08-26 CA CA2809369A patent/CA2809369A1/en not_active Abandoned
-
2013
- 2013-03-15 CO CO13052190A patent/CO6700829A2/es unknown
-
2015
- 2015-05-06 US US14/705,842 patent/US20150322166A1/en not_active Abandoned
-
2016
- 2016-02-22 JP JP2016030708A patent/JP2016119906A/ja active Pending
- 2016-04-14 AU AU2016202380A patent/AU2016202380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP7308191B2 (ja) | 抗ｃｄ４７剤ベースの卵巣癌療法 | |
| CN111699005A (zh) | 使用抗cd47抗体和抗cd20抗体的抗癌方案 | |
| US10611839B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
| WO2019222188A1 (en) | Methods of treating cancer | |
| AU2016213773A1 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF | |
| JP2014193862A (ja) | 新規な抗ｉｇｆ−ｉｒ抗体及びその使用 | |
| Smith et al. | PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma | |
| HUE030578T2 (en) | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation | |
| RU2013113638A (ru) | МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| TR201903026T4 (en) | S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES. | |
| US11667700B2 (en) | Anti-PCNA monoclonal antibodies and use thereof | |
| JP2019517504A (ja) | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断 | |
| CN119656302A (zh) | 治疗主体中c1013g/cxcr4相关的华氏巨球蛋白血症的药物组合物、评估方法及药剂盒 | |
| JP2023113613A (ja) | チェックポイント阻害薬のための予測末梢血バイオマーカー | |
| CN117321418A (zh) | 癌症生物标志物及其使用方法 | |
| WO2020040245A1 (ja) | 抗体薬物複合体の感受性マーカー | |
| JP2022519649A (ja) | がんの診断および治療方法 | |
| JP2021502344A (ja) | 腫瘍を処置する方法 | |
| JP2023526044A5 (enExample) | ||
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| JP2025124676A (ja) | インテグリンα１０および侵攻性癌型 | |
| WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| EP4593961A1 (en) | Treatment of drug-resistant hepatocellular carcinoma | |
| JP2022549337A (ja) | がん療法のための複合バイオマーカー |